Christine M Khosropour1, Olusegun O Soge2,3, Matthew R Golden1,3,4, James P Hughes5, Lindley A Barbee3,4. 1. Department of Epidemiology, University of Washington, Seattle, Washington, USA. 2. Department of Global Health, University of Washington, Seattle, Washington, USA. 3. Department of Medicine, University of Washington, Seattle, Washington, USA. 4. Public Health-Seattle & King County HIV/STD Program, Seattle, Washington, USAand. 5. Department of Biostatistics, University of Washington, Seattle, Washington, USA.
Abstract
BACKGROUND: The prevalence of pharyngeal chlamydia is low, but its incidence and duration are unknown. A high incidence or duration may support the role of pharyngeal chlamydia in sustaining chlamydia transmission. METHODS: From March 2016 to December 2018, we enrolled men who have sex with men (MSM) in a 48-week cohort study in Seattle, Washington. Participants self-collected pharyngeal specimens weekly. We tested specimens using nucleic acid amplification testing at the conclusion of the study. In primary analyses, we defined incident pharyngeal chlamydia as >2 consecutive weeks of a positive pharyngeal specimen. In sensitivity analyses, we defined incident chlamydia as >1 week of a positive specimen. We estimated duration of pharyngeal chlamydia, censoring at loss to follow-up, receipt of antibiotics, or end of study. RESULTS: A total of 140 participants contributed 70.5 person-years (PY); 1.4% had pharyngeal chlamydia at enrollment. In primary analyses, there were 8 pharyngeal chlamydia cases among 6 MSM (incidence = 11.4 per 100 PY; 95% confidence interval [CI]: 6.0-21.9). In sensitivity analysis, there were 19 cases among 16 MSM (incidence = 27.1 per 100 PY; 95% CI: 18.5-39.8). The median duration was 6.0 weeks (95% CI: 2.0-undefined) in primary analysis and 2.0 weeks (95% CI: 1.1-6.0) in sensitivity analysis. Duration was shorter for those with a history of chlamydia compared with those without (3.6 vs 8.7 weeks; P = .02). CONCLUSIONS: Pharyngeal chlamydia has a low incidence and duration relative to other extragenital sexually transmitted infections. Its contribution to population-level transmission remains unclear.
BACKGROUND: The prevalence of pharyngeal chlamydia is low, but its incidence and duration are unknown. A high incidence or duration may support the role of pharyngeal chlamydia in sustaining chlamydia transmission. METHODS: From March 2016 to December 2018, we enrolled men who have sex with men (MSM) in a 48-week cohort study in Seattle, Washington. Participants self-collected pharyngeal specimens weekly. We tested specimens using nucleic acid amplification testing at the conclusion of the study. In primary analyses, we defined incident pharyngeal chlamydia as >2 consecutive weeks of a positive pharyngeal specimen. In sensitivity analyses, we defined incident chlamydia as >1 week of a positive specimen. We estimated duration of pharyngeal chlamydia, censoring at loss to follow-up, receipt of antibiotics, or end of study. RESULTS: A total of 140 participants contributed 70.5 person-years (PY); 1.4% had pharyngeal chlamydia at enrollment. In primary analyses, there were 8 pharyngeal chlamydia cases among 6 MSM (incidence = 11.4 per 100 PY; 95% confidence interval [CI]: 6.0-21.9). In sensitivity analysis, there were 19 cases among 16 MSM (incidence = 27.1 per 100 PY; 95% CI: 18.5-39.8). The median duration was 6.0 weeks (95% CI: 2.0-undefined) in primary analysis and 2.0 weeks (95% CI: 1.1-6.0) in sensitivity analysis. Duration was shorter for those with a history of chlamydia compared with those without (3.6 vs 8.7 weeks; P = .02). CONCLUSIONS: Pharyngeal chlamydia has a low incidence and duration relative to other extragenital sexually transmitted infections. Its contribution to population-level transmission remains unclear.
Authors: Sepehr N Tabrizi; Magnus Unemo; Athena E Limnios; Tiffany R Hogan; Stig-Ove Hjelmevoll; Susanne M Garland; John Tapsall Journal: J Clin Microbiol Date: 2011-08-03 Impact factor: 5.948
Authors: Lindley A Barbee; Christine M Khosropour; Julia C Dombrowski; Lisa E Manhart; Matthew R Golden Journal: Sex Transm Infect Date: 2015-08-21 Impact factor: 3.519
Authors: Ymke J Evers; Nicole H T M Dukers-Muijrers; Geneviève A F S van Liere; Jan van Bergen; Sophie Kuizenga-Wessel; Christian J P A Hoebe Journal: Clin Infect Dis Date: 2022-04-28 Impact factor: 20.999
Authors: Kimberly A Workowski; Laura H Bachmann; Philip A Chan; Christine M Johnston; Christina A Muzny; Ina Park; Hilary Reno; Jonathan M Zenilman; Gail A Bolan Journal: MMWR Recomm Rep Date: 2021-07-23
Authors: Kyle T Bernstein; Sally C Stephens; Pennan M Barry; Robert Kohn; Susan S Philip; Sally Liska; Jeffrey D Klausner Journal: Clin Infect Dis Date: 2009-12-15 Impact factor: 9.079
Authors: Lindley A Barbee; Olusegun O Soge; Christine M Khosropour; Micaela Haglund; Winnie Yeung; James Hughes; Matthew R Golden Journal: Clin Infect Dis Date: 2021-08-16 Impact factor: 9.079
Authors: Dyani Lewis; Danielle C Newton; Rebecca J Guy; Hammad Ali; Marcus Y Chen; Christopher K Fairley; Jane S Hocking Journal: BMC Infect Dis Date: 2012-05-14 Impact factor: 3.090
Authors: Lindley A Barbee; Christine M Khosropour; Olusegun O Soge; James P Hughes; Micaela Haglund; Winnie Yeung; Matthew R Golden Journal: Clin Infect Dis Date: 2022-05-03 Impact factor: 20.999
Authors: Philip A Chan; Ashley Robinette; Madeline Montgomery; Alexi Almonte; Susan Cu-Uvin; John R Lonks; Kimberle C Chapin; Erna M Kojic; Erica J Hardy Journal: Infect Dis Obstet Gynecol Date: 2016-06-05
Authors: Nicole H T M Dukers-Muijrers; Ymke J Evers; Christian J P A Hoebe; Petra F G Wolffs; Henry J C de Vries; Bernice Hoenderboom; Marianne A B van der Sande; Janneke Heijne; Jeffrey D Klausner; Jane S Hocking; Jan van Bergen Journal: BMC Infect Dis Date: 2022-03-14 Impact factor: 3.090